Why the study?
Does drug-coated balloon treatment provide non-inferior outcomes compared to stenting with bare metal or drug-eluting stents in patients with NSTEMI and coronary de novo lesions?
Does drug-coated balloon treatment provide non-inferior outcomes compared to stenting with bare metal or drug-eluting stents in patients with NSTEMI and coronary de novo lesions?
In patients with NSTEMI and de novo coronary lesions, treatment with drug-coated balloons was non-inferior to bare metal or drug-eluting stents.
Supports DCB as a stent alternative in NSTEMI de novo lesions; extends randomized evidence to acute settings.
In patients with NSTEMI, treatment of coronary de novo lesions with DCB was non-inferior to stenting with BMS or DES. These data warrant further investigation of DCB in this setting, in larger trials with DES as comparator (ClinicalTrials.gov Identifier: NCT01489449).
No takes yet. Share an insight, caveat, or question.
Scheller et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: